CRISPR Therapeutics AG
CRSP
株式のランク
#3578
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
株価
$49.25
最終同期: 2026-10-16
時価総額
$4.76B
変化（1日）
-4.42%
変化（1年）
-28.78%
国
CH
取引 CRISPR Therapeutics AG (CRSP)
カテゴリー
Healthcare
CRISPR Therapeutics AG（CRSP）の営業利益率
October 2026 時点の営業利益率 TTM: -3,971.53%
CRISPR Therapeutics AG の最新の財務報告と株価によると、現在の営業利益率（TTM）は -3,971.53% です。2023 年末時点では -59.95% でした。
CRISPR Therapeutics AG の営業利益率の履歴（2014 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -3,971.53% | 197.93% |
| 2024 | -1,333.05% | 2,123.60% |
| 2023 | -59.95% | -99.96% |
| 2022 | -154,394.72% | -377,500.93% |
| 2021 | 40.91% | -100.06% |
| 2020 | -65,273.48% | -404,520.57% |
| 2019 | 16.14% | -100.32% |
| 2018 | -5,087.80% | 3,126.46% |
| 2017 | -157.69% | -88.05% |
| 2016 | -1,319.33% | -87.33% |
| 2015 | -10,416.60% | 0.00% |
| 2014 | 0.00% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。